NCT01059825 - Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) | Biotech Hunter

Enrollment

375

Participants

Timeline

Start Date

February 24, 2010

Primary Completion Date

January 20, 2011

Study Completion Date

January 20, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo to Ertugliflozin

Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

DRUG

Ertugliflozin 1 mg

Tablet, 1 mg, once daily for 84 days

DRUG

Ertugliflozin 5 mg

Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days

DRUG

Ertugliflozin 25 mg

Tablet, 25 mg, once daily for 84 days

DRUG

Sitagliptin 100 mg

Tablet, 100 mg, once daily for 84 days

DRUG

Placebo to Sitagliptin

Tablet, matching placebo to 100 mg, once daily for 84 days

DRUG

Metformin

Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).